Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity by unknown
BRIEF REPORT
Randomized, Double-Blind Study of the Safety
of the Liquid Versus Lyophilized Formulation
of Palivizumab in Premature Infants and Children
with Chronic Lung Disease of Prematurity
Doris Makari • Kathryn M. Jensen • Brian Harris • Hasan S. Jafri
To view enhanced content go to www.infectiousdiseases-open.com
Received: June 30, 2014 / Published online: August 26, 2014
 The Author(s) 2014. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: To avoid the need for
reconstitution required by lyophilized
palivizumab, a liquid formulation was
developed. This study assessed the safety and
antidrug antibodies (ADA) of the liquid
formulation of palivizumab compared with the
lyophilized formulation.
Methods: This phase 4, randomized, double-
blind, multicenter study included children with
chronic lung disease of prematurity who were
B24 months of age and children born
prematurely with a gestational age of
B35 weeks who were B6 months of age at
randomization. Subjects were randomized 1:1
to 15 mg/kg of either liquid or lyophilized
palivizumab administered via intramuscular
injection every 30 days for a total of 5
injections. Safety was assessed based on serious
adverse events (SAEs). ADA to palivizumab was
assessed using blood collected at baseline and at
a time point between study days 240 and 300.
Results: A total of 413 subjects were included
in the analyses. The incidence of SAEs reported
was 8.5% with liquid palivizumab and 5.9%
with lyophilized palivizumab; none were
deemed drug-related. The reported SAEs were
consistent with expected conditions in this
pediatric age group; there was no increase in
respiratory syncytial virus (RSV) disease with
liquid palivizumab. At study days 240–300,
antipalivizumab antibodies were detected in
none of the subjects in the liquid palivizumab
group and in 1 subject in the lyophilized group.
The true ADA percent positive, based on the
upper limit of the 95% confidence interval (CI),
was \1.5% for both treatments combined.
Conclusion: The frequency of detection of
ADAs was low. The true ADA percent positive
for both treatment groups combined based on
the upper limit of the 95% CI was \1.5%. The
type and frequency of SAEs reported were as
expected, and there was no evidence of an
increase in RSV disease with liquid
palivizumab.
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INTRODUCTION
Respiratory syncytial virus (RSV) is a major
respiratory viral pathogen in infants and
young children worldwide; there were
approximately 34 million cases of RSV-
associated acute lower respiratory tract
infection in children \5 years of age globally
in 2005 [1]. Approximately 10% of these cases
(3.4 million) were severe enough to require
hospital admission, and there were
approximately 200,000 deaths [1]. Risk
factors for severe RSV disease include preterm
birth (born at B35 weeks gestation), congenital
heart disease, and chronic lung disease of
prematurity [2].
Respiratory syncytial virus immune
globulin intravenous (RSV-IGIV; RespiGam,
MedImmune; Gaithersburg, MD, USA) was the
first product used for preventing severe RSV
disease and required a 4-h intravenous infusion.
Palivizumab (MedImmune), an F-protein-
specific humanized monoclonal antibody, was
an advance in RSV prevention, as it could be
given intramuscularly [3]. Palivizumab, first
licensed in the United States in 1998, is
indicated for the prevention of serious lower
respiratory tract disease due to RSV in children
at high risk of RSV disease [4]. It is currently
licensed in more than 80 countries [5]. The
efficacy of palivizumab has been established in
three randomized, placebo-controlled studies
[6–8]. Initially, palivizumab was available only
in a lyophilized formulation that required
reconstitution with sterile water to a
concentration of 50 or 100 mg/mL [9]. To
avoid the need for reconstitution, a liquid
formulation of palivizumab was developed [9].
The liquid formulation of palivizumab allows
for more simplified administration, which is
valuable for healthcare providers and decreases
the amount of time high-risk infants must
spend in a waiting room with potential
exposure to other sick children. Additionally,
liquid palivizumab reduces the potential error
in amount of medication administered that
could occur from improper reconstitution of
the medication [10]. After the liquid
formulation was assessed for safety in adults
[11], a study of children B6 months of age with
a history of prematurity showed that these 2
formulations of palivizumab were bioequivalent
with a similar safety profile, leading to the
approval of liquid palivizumab by the US Food
and Drug Administration in 2004 [12]. In
addition, antidrug antibodies (ADA) can
negatively affect the pharmacokinetics and
pharmacodynamics of a drug, leading to
potential adverse effects or loss of efficacy [13].
This study measured ADA approximately
4–7 months after the last dose of study
medication, which had not been previously
studied.
This study was a postmarketing
commitment and assessed the safety and
ADAs of the liquid formulation of
palivizumab compared with the lyophilized
formulation in children at high risk for the
development of serious RSV disease.
METHODS
Subjects
The study included medically stable children
with chronic lung disease of prematurity who
were B24 months of age at randomization and
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children born prematurely with a gestational
age of B35 weeks who were B6 months of age at
randomization. Children were excluded if they
received lyophilized palivizumab, IGIV, or other
RSV-specific monoclonal antibody within
3 months before randomization, were
receiving mechanical ventilation at the time of
study entry, had congenital heart disease, acute
respiratory or other acute infection or illness, a
life expectancy of \6 months, or had a mother
diagnosed with human immunodeficiency
virus, unless the child had been proven to not
be infected.
Study approval was obtained by the
individual Institutional Review Boards of some
sites, whereas approval was obtained by a
centralized Institutional Review Board
(Chesapeake IRB, Columbia, MD, USA) for the
remaining sites. The study was conducted in
accordance with the Declaration of Helsinki.
Written informed consent was obtained from
each study subject’s parent or legal guardian
before study entry.
Study Drug
Study medication was administered via
intramuscular injection every 30 days during
the RSV season, for a total of 5 injections. All
subjects were scheduled to receive 5 injections.
Liquid palivizumab was supplied in sterile vials
containing 100 mg of palivizumab in 1 mL of a
sterile, preservative-free liquid, formulated with
25 mM histidine and 1.6 mM glycine.
Lyophilized palivizumab was supplied in
sterile vials containing 100 mg of sterile
lyophilized product that when formulated
contained 25 mM histidine, 1.6 mM glycine,
and 3% mannitol. Lyophilized palivizumab
required reconstitution with 1 mL of sterile
water for injection to yield palivizumab at a
concentration of 100 mg/mL. Liquid and
lyophilized palivizumab were similar in
formulation with the exception of the
excipients.
Study Design
This phase 4, randomized, double-blind,
multicenter study enrolled subjects over 2 RSV
seasons (ClinicalTrials.gov #NCT00233064)
from October 2005 to October 2007 across 51
sites in the United States. Subjects were
randomized 1:1 to 15 mg/kg of palivizumab
liquid or lyophilized formulation.
The study was conducted in a double-blind
manner with the medical monitor, statistician,
project management, site monitors, data
management, subjects’ parents, and the
clinical site staff blinded to study treatment
assignment throughout the study. An
independent monitor who only received
pharmacy records and the investigational
agent manager at the study site were the only
people with access to information that
identified a subject’s treatment allocation.
Neither individual was to reveal to anyone the
treatment arm to which a subject was assigned.
The study drug was supplied to the
pharmacy as open-label vials of liquid or
lyophilized palivizumab. The investigational
agent manager prepared the study drug and
dispensed it in identically appearing syringes,
labeled using the subjects’ initials.
Safety
Safety was assessed based on serious adverse
events (SAEs). Subjects were monitored through
study day 150 or until the resolution of any
serious events, whichever was longer. SAEs were
defined as those that resulted in death, were
life-threatening, led to hospitalization, or
prolongation of an existing hospitalization.
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SAEs were graded by severity (mild, moderate,
severe, or life-threatening) and by relationship
to study drug (none, remote, possible, probable,
or definite) as determined by the principal
investigator.
Antidrug Antibodies
ADA to palivizumab was assessed using blood
collected at baseline before the first dose of
study medication and at 1 time point between
study days 240 and 300 (approximately
4–7 months after the last dose of study
medication). Antipalivizumab antibody
analyses were performed at PPD (Richmond,
VA, USA) using a validated enzyme-linked
immunosorbent assay (ELISA) (developed by
MedImmune) [14]. Controls were prepared by
adding a goat polyclonal antipalivizumab
antibody into normal human serum. Duplicate
determinations of the positive control and
negative controls were performed. Results were
analyzed using Softmax Pro 4.8 software
(Molecular Devices Corporation. Sunnyvale,
CA, USA). Positive unknown samples were
titered on a second plate beginning with the
original sample and diluting 1:2 with normal
human serum across the plate in duplicate. The
endpoint titer was defined as the highest serum
dilution tested that showed a positive response.
The lowest dilution value for which a positive
result could be obtained was 1:10 because all
samples were diluted 1:10 before performing
the assay.
Statistical Analyses
The safety analysis included all subjects who
received any study medication. The ADA
analysis included subjects who received C2
doses of study medication and had C1 blood
sample collected. The sample size calculation
was based on findings from the pivotal phase 3
study [6], which showed approximately 1%
detection of ADA after a single season of
dosing with lyophilized palivizumab. A sample
size of 200 per treatment group was chosen so
that the upper limit of the 95% confidence
interval (CI) would be below 3%.
Categorical data were summarized by the
number and percent of subjects in each
category. To determine the percent positive
ADA, 95% CIs were also calculated. No formal
tests of comparison were planned or conducted.
Statistical analyses were conducted using the
SAS System software version 6.12 and/or 8.2




A total of 417 subjects were randomized into the
study across the 51 sites in the United States,
and 413 subjects were followed and included in
all of the safety analyses; 4 subjects from 1 site
were excluded from the analyses because the
site did not provide any additional information
or data regarding the subjects other than the
fact that they received all 5 doses of
palivizumab. Of the 413 subjects, 211 were
randomized into the liquid palivizumab group
and 202 were randomized into the lyophilized
palivizumab group. Overall, 26/413 (6.3%)
subjects did not complete the study. The most
common reasons for not completing the study
were lost to follow-up [14/413 (3.4%)] and
withdrawal of consent [8/413 (1.9%); Fig. 1].
Demographic and baseline characteristics,
including age, gender, race, and weight, were
similar between the liquid and lyophilized
palivizumab groups (Table 1).
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Safety
The majority of subjects in both study groups
received all 5 doses of medication [94.8% (200/
211) in the liquid palivizumab group and 95%
(192/202) in the lyophilized palivizumab
group]. The incidence of SAEs reported was
8.5% (18/211) with liquid palivizumab and
5.9% (12/202) with lyophilized palivizumab
(Table 2). The reported SAEs were consistent
with common conditions in this pediatric age
group. The most common SAEs (i.e., those
occurring in C2 subjects) were bronchiolitis,
gastroenteritis, respiratory distress, viral
infection, cleft lip, and inguinal hernia
(Table 2). The incidence of bronchiolitis was
2.8% (6/211) in the liquid palivizumab group
and 1.5% (3/202) in the lyophilized
palivizumab group. One subject in the
lyophilized palivizumab group died of
asphyxia during the study, but the death was
deemed not related to the study medication by
the study investigator. None of the SAEs were
determined by the investigators to be related to
study medication.
By system organ class, 2 system organ classes
had [1 percentage point difference between
treatment groups: infections and infestations
[liquid, 6.2% (95% CI 3.3%, 10.3%); lyophilized
3.0% (1.1%, 6.42%)] and respiratory, thoracic
and mediastinal disorders [liquid, 0.0% (0.0%,
1.7%); lyophilized, 2.0% (0.5%, 5.0%)]. For
infections and infestations, SAEs that may
have contributed to a higher incidence in the
liquid palivizumab group included bronchiolitis
and viral infection. There was no evidence of an
Fig. 1 Disposition of subjects. ADA Antidrug antibody, CRF case report form
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increase in RSV disease with liquid palivizumab.
Of the 9 events of bronchiolitis, 7 were tested
locally for RSV (liquid, n = 5; lyophilized, n = 2)
and all 7 were negative. A single event of
bronchopneumonia (in the liquid palivizumab
group) was tested locally and was negative for
RSV. Both events of viral infection were
negative for RSV based on local testing.
The events of respiratory, thoracic and
mediastinal disorders reported in the
lyophilized palivizumab group were respiratory
distress (2 subjects), and apnea, asphyxia, and
dyspnea (each in 1 subject). The SAE of
asphyxia resulted in death (described above).
The remaining events occurred sporadically
throughout dosing; all required hospitalization
and resolved within 2–10 days after treatment.
The events of apnea, dyspnea, and asphyxia
were tested locally for RSV and all were
negative.







Mean (SD) 4.0 (4.2) 4.6 (4.5) 4.3 (4.3)
Median 2.9 3.4 3.2
Range 0.2–22.9 0.2–23.6 0.2–23.6
Gestational age (weeks)
Mean (SD) 32.7 (2.5) 32.4 (2.7) 32.5 (2.6)
Median 34.0 33.0 34.0
Range 24–36 24–38 24–38
Gender, n (%)
Male 103 (51.0) 107 (50.7) 210 (50.8)
Race, n (%)
White/non-Hispanic 149 (73.8) 151 (71.6) 300 (72.6)
Black 24 (11.9) 25 (11.8) 49 (11.9)
Hispanic 14 (6.9) 22 (10.4) 36 (8.7)
Asian 3 (1.5) 1 (0.5) 4 (1.0)
Other 12 (5.9) 12 (5.7) 24 (5.8)
Weight at day 0 (kg)
Mean (SD) 5.1 (2.3) 5.3 (2.3) 5.2 (2.3)
Median 4.74 5.20 5.00
Range 1.8–13.8 1.8–14.5 1.8–14.5
CLD of prematurity, n (%)
Yes 26 (12.9) 35 (16.6) 61 (14.8)
CLD Chronic lung disease, SD standard deviation
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Antidrug Antibodies
At baseline, none of the subjects exhibited
antipalivizumab antibodies. From study days
240–300, antipalivizumab antibodies were
detected in none of the subjects in the liquid
palivizumab group and in 1/188 subject (0.5%)
in the lyophilized palivizumab group (at
Table 2 Serious adverse events






Total number of subjects
reporting C1 SAE
12 (5.9) 18 (8.5) 30 (7.3)
Bronchiolitis 3 (1.5) 6 (2.8) 9 (2.2)
Gastroenteritis 2 (1.0) 2 (0.9) 4 (1.0)
Respiratory distress 2 (1.0) 0 (0.0) 2 (0.5)
Viral infection 0 (0.0) 2 (0.9) 2 (0.5)
Cleft lip 1 (0.5) 1 (0.5) 2 (0.5)
Inguinal hernia 1 (0.5) 1 (0.5) 2 (0.5)
Abscess 1 (0.5) 0 (0.0) 1 (0.2)
Anal ﬁssure 0 (0.0) 1 (0.5) 1 (0.2)
Apnea 1 (0.5) 0 (0.0) 1 (0.2)
Asphyxia 1 (0.5) 0 (0.0) 1 (0.2)
Bronchopneumonia 0 (0.0) 1 (0.5) 1 (0.2)
Cellulitis 0 (0.0) 1 (0.5) 1 (0.2)
Complex partial seizures 0 (0.0) 1 (0.5) 1 (0.2)
Convulsions 0 (0.0) 1 (0.5) 1 (0.2)
Craniosynostosis 0 (0.0) 1 (0.5) 1 (0.2)
Dehydration 0 (0.0) 1 (0.5) 1 (0.2)
Dyspnea 1 (0.5) 0 (0.0) 1 (0.2)
Failure to thrive 1 (0.5) 0 (0.0) 1 (0.2)
Gastroenteritis rotavirus 0 (0.0) 1 (0.5) 1 (0.2)
Gastroesophageal reﬂux disease 0 (0.0) 1 (0.5) 1 (0.2)
Hydronephrosis 0 (0.0) 1 (0.5) 1 (0.2)
Infectious croup 0 (0.0) 1 (0.5) 1 (0.2)
Lymphadenitis 0 (0.0) 1 (0.5) 1 (0.2)
Occult blood positive 1 (0.5) 0 (0.0) 1 (0.2)
Umbilical hernia 0 (0.0) 1 (0.5) 1 (0.2)
SAE Serious adverse event
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154 days post final dose), with an overall
percent positive of 0.3% (1/379) for both
treatment groups combined. Given these
observations and the number of subjects
studied, the true ADA percent positive, based
on the upper limit of the exact 95% CI, is at
most 1.9% for the liquid palivizumab group,
2.9% for the lyophilized palivizumab group,
and 1.5% for both treatments combined.
DISCUSSION
Liquid palivizumab was developed to avoid the
need for reconstitution required by lyophilized
palivizumab. Since 2006, liquid palivizumab has
been the only formulation distributed in the
United States, and is estimated to have been
administered to one million infants [15].
Findings from this study of children at high
risk for serious RSV disease showed that liquid
and lyophilized formulations exhibit a
comparable safety profile with similar reported
SAEs.
The present safety findings generally are
consistent with findings from a randomized,
double-blind, cross-over study of infants aged
B6 months who were born B35 weeks
gestational age [12]. In that study, the
percentages of infants with SAEs were similar
(liquid, 3.3%; lyophilized, 2.6%) [12]. The type
and frequency of SAEs reported were similar
between the liquid and lyophilized palivizumab
groups [12]. The incidence of bronchiolitis SAE
reported was also similar between the 2 groups
(liquid, 2.8%; lyophilized, 1.5%).
The ADA results in the present and previous
studies were based on positive palivizumab
antibodies using an ELISA, which is limited in
its ability to detect antipalivizumab antibodies
in the presence of palivizumab [4]. In the
present study, the true ADA percent positive
for both treatment groups combined based on
the upper limit of the 95% CI was at most 1.5%.
The 0.5% observed ADA percent positive (with
an upper limit of the 95% CI of 2.9%) for
lyophilized palivizumab reported in the present
study was consistent with the 1.2% observed
ADA percent positive reported in a previous
phase 3 trial of lyophilized palivizumab in 1,502
children [6]. In another previous trial of high-
risk preterm children B24 months of age, the
ADA percent positive was 0.3% for both
palivizumab formulations combined [4]. It is
possible that the ADA percent positive in both
study arms of the present study could have been
higher had the current drug-tolerant
electrochemiluminescence (ECLA) assay been
used. However, 2 studies of liquid palivizumab
recipients that used an ECLA to determine ADA
also demonstrated ADA percents positive of
1.1% and 1.5% [4].
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